As biologics gain greater prominence, protein engineers are adapting to new indications, new advances in targeting science, new product formats, and products that are truly differentiated in the marketplace. The Protein Engineering & Development pipeline
offers a weeklong exploration of state-of-the-art approaches for developing safe and effective protein and antibody-based therapeutics, including improving product qualities, optimizing lead and candidate selection, and the application of deep sequencing
and single cell analysis.
Recombinant Protein Therapeutics
Lead and Candidate Selection for Therapeutic Proteins
Deep Sequencing and Single Cell Analysis for Antibody Discovery
Aris N. Economides, PhD, Vice President, Research, Regeneron Pharmaceuticals, Inc.
Peter M. Tessier, PhD, Professor, Pharmaceutical Sciences, Chemical Engineering and Biomedical Engineering, University of Michigan
Bryan Briney, PhD, Assistant Professor, Immunology and Microbiology, The Scripps Research Institute